Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Dayu Shi, Hongxia Shi, Xiaoli Liu, Minghui Duan, Junling Zhuang, Xin Du, Ling Qin, Wuhan Hui, Rong Liang, Meifang Wang, Ye Chen, Dongyun Li, Wei Yang, Gusheng Tang, Weihua Zhang, Xia Kuang, Wei Su, Yanqiu Han, Limei Chen, Jihong Xu, Zhuogang Liu, Jian Huang, Chunting Zhao, Hongyan Tong, Jianda Hu, Chunyan Chen, Xiequn Chen, Zhijian Xiao & Qian Jiang. (2021) Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms. Leukemia & Lymphoma 62:11, pages 2703-2715.
Read now
Read now
Barbara Mora & Francesco Passamonti. (2019) Developments in diagnosis and treatment of essential thrombocythemia. Expert Review of Hematology 12:3, pages 159-171.
Read now
Read now
Nana Brochmann, Esben Meulengracht Flachs, Anne Illemann Christensen, Christen Lykkegaard Andersen, Knud Juel, Hans Carl Hasselbalch & Ann-Dorthe Zwisler. (2017) A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents. Clinical Epidemiology 9, pages 141-150.
Read now
Read now
Sarah Chuzi & Brady L. Stein. (2017) Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery. Leukemia & Lymphoma 58:12, pages 2786-2798.
Read now
Read now
Mads Emil Bjørn & Hans Carl Hasselbalch. (2017) Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. Expert Review of Hematology 10:5, pages 393-404.
Read now
Read now
Kris Vaddi, Srdan Verstovsek & Jean-Jacques Kiladjian. (2016) Ruxolitinib: a targeted treatment option for patients with polycythemia vera. Blood and Lymphatic Cancer: Targets and Therapy 6, pages 7-19.
Read now
Read now
Jean-Jacques Kiladjian, Elliott F Winton, Moshe Talpaz & Srdan Verstovsek. (2015) Ruxolitinib for the treatment of patients with polycythemia vera. Expert Review of Hematology 8:4, pages 391-401.
Read now
Read now
Srdan Verstovsek & Rami S Komrokji. (2015) Novel and emerging therapies for the treatment of polycythemia vera. Expert Review of Hematology 8:1, pages 101-113.
Read now
Read now
Tariq I Mughal, Kris Vaddi, Nicholas J Sarlis & Srdan Verstovsek. (2014) Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. International Journal of General Medicine 7, pages 89-101.
Read now
Read now
Johanna Abelsson, Björn Andréasson, Jan Samuelsson, Malin Hultcrantz, Elisabeth Ejerblad, Berit Johansson, Robyn Emanuel, Ruben Mesa & Peter Johansson. (2013) Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leukemia & Lymphoma 54:10, pages 2226-2230.
Read now
Read now
Richard T Silver, Jean-Jacques Kiladjian & Hans Carl Hasselbalch. (2013) Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Review of Hematology 6:1, pages 49-58.
Read now
Read now
Raoul Tibes, James M Bogenberger & Ruben A Mesa. (2012) Recent developments in myelofibrosis. Blood and Lymphatic Cancer: Targets and Therapy 2, pages 125-136.
Read now
Read now
Articles from other publishers (30)
Ashleigh Bradford, Ken Young, Ashley Whitechurch, Kate Burbury & Elizabeth Jane M. Pearson. (2022) Disabled, invisible and dismissed—The lived experience of fatigue in people with myeloproliferative neoplasms. Cancer Reports 6:1.
Crossref
Crossref
Jeanne Palmer & Ruben Mesa. 2017. Holland‐Frei Cancer Medicine. Holland‐Frei Cancer Medicine
1
13
.
Henriette Knold Rossau, Mette Kjerholt, Nana Brochmann, Lars Hermann Tang & Karin Brochstedt Dieperink. (2021) Daily living and rehabilitation needs in patients and caregivers affected by myeloproliferative neoplasms (MPN): A qualitative study. Journal of Clinical Nursing 31:7-8, pages 909-921.
Crossref
Crossref
Avanthika Venkatachalam, Eli Pikarsky & Yinon Ben-Neriah. (2022) Putative homeostatic role of cancer driver mutations. Trends in Cell Biology 32:1, pages 8-17.
Crossref
Crossref
Nana Brochmann, Esben Meulengracht Flachs, Anne Illemann Christensen, Marie Bak, Christen Lykkegaard Andersen, Knud Juel & Ann-Dorthe Zwisler. (2020) Health-Related Quality of Life in Patients with Philadelphia-Negative Myeloproliferative Neoplasms: A Nationwide Population-Based Survey in Denmark. Cancers 12:12, pages 3565.
Crossref
Crossref
Ahmet PEKER, Sevgi PEKER, Mehmet Can UGUR, Cengiz CEYLAN & Hakan YARKICI. (2020) Esansiyel trombositoz ve polisitemi vera hastalarında depresyon ve anksiyete düzeyleri ile yaşam kalitesi arasındaki ilişki. Pamukkale Medical Journal, pages 785-793.
Crossref
Crossref
Emma Bergfelt Lennmyr, Karin Karlsson, Marie Abrahamsson, Fereshte Ebrahim, Anna Lübking, Martin Höglund, Gunnar Juliusson & Heléne Hallböök. (2020) Introducing patient‐reported outcome in the acute leukemia quality registries in Sweden. European Journal of Haematology 104:6, pages 571-580.
Crossref
Crossref
Ruben A. Mesa, Yun Su, Adrien Woolfson, Josef T. Prchal, Kathleen Turnbull, Elias Jabbour, Robyn Scherber, Alan L. Shields, Meaghan Krohe, Funke Ojo, Farrah Pompilus, Joseph C. Cappelleri & Claire Harrison. (2019) Development of a symptom assessment in patients with myelofibrosis: qualitative study findings. Health and Quality of Life Outcomes 17:1.
Crossref
Crossref
Jeanne Palmer, Heidi E. Kosiorek, Christine Wolschke, Veena D.S. Fauble, Richard ButterfieldIIIIII, Holly Geyer, Robyn M. Scherber, Amylou C. Dueck, Allison Gathany, Ruben A. Mesa & Nicolaus Kroger. (2019) Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis. Biology of Blood and Marrow Transplantation 25:11, pages 2267-2273.
Crossref
Crossref
Claire Harrison, Jonathan Mathias, Maz Campbell‐Drew, Adam J. Mead, Zack Pemberton‐Whiteley, Sahra Ali, Frances Wadelin, Gavin Taylor‐Stokes, John Waller & Barbara Taylor. (2019)
UK
results from the myeloproliferative neoplasms (
MPN
) landmark survey on the symptom, emotional and economic burden of
MPN
. British Journal of Haematology 186:3.
Crossref
Crossref
Stal Marina. (2019) Myeloproliferative Neoplasms: Fatigue, depression & hemoglobi. Archives of Hematology Case Reports and Reviews 4:1, pages 014-019.
Crossref
Crossref
Laura F. Mendez Luque, Amanda L. Blackmon, Gajalakshmi Ramanathan & Angela G. Fleischman. (2019) Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms. Current Hematologic Malignancy Reports 14:3, pages 145-153.
Crossref
Crossref
Michael R. Grunwald, Brady L. Stein, Ralph V. Boccia, Stephen T. Oh, Dilan Paranagama, Shreekant Parasuraman, Philomena Colucci & Ruben Mesa. (2018) Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clinical Lymphoma Myeloma and Leukemia 18:12, pages 788-795.e2.
Crossref
Crossref
Kasper Mønsted Pedersen, Graziella Zangger, Nana Brochmann, Birk Mygind Grønfeldt, Ann-Dorthe Zwisler, Hans Carl Hasselbalch & Lars Hermann Tang. (2018) The effectiveness of exercise-based rehabilitation to patients with myeloproliferative neoplasms-An explorative study. European Journal of Cancer Care 27:5, pages e12865.
Crossref
Crossref
Ruben Mesa, Ralph V. Boccia, Michael R. Grunwald, Stephen T. Oh, Philomena Colucci, Dilan Paranagama, Shreekant Parasuraman & Brady L. Stein. (2018) Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clinical Lymphoma Myeloma and Leukemia 18:9, pages 590-596.
Crossref
Crossref
Francesca Palandri, Giulia Benevolo, Alessandra Iurlo, Elisabetta Abruzzese, Angelo M. Carella, Chiara Paoli, Giuseppe A. Palumbo, Massimiliano Bonifacio, Daniela Cilloni, Alessandro Andriani, Attilio Guarini, Diamante Turri, Elena Maria Elli, Antonietta Falcone, Barbara Anaclerico, Pellegrino Musto, Nicola Di Renzo, Mario Tiribelli, Renato Zambello, Caterina Spinosa, Alessandra Ricco, Letizia Raucci, Bruno Martino, Mario Annunziata, Silvia Pascale, Anna Marina Liberati, Giorgio La Nasa, Margherita Maffioli, Massimo Breccia, Novella Pugliese, Silvia Betti, Gianfranco Giglio, Antonietta Cappuccio & Luigi Reale. (2018) Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project. Quality of Life Research 27:6, pages 1545-1554.
Crossref
Crossref
Shreekant V. ParasuramanNianwen ShiDilan C. ParanagamaMachaon Bonafede. (2018) Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera. Journal of Managed Care & Specialty Pharmacy 24:1, pages 47-55.
Crossref
Crossref
Claire N. Harrison, Steffen Koschmieder, Lynda Foltz, Paola Guglielmelli, Tina Flindt, Michael Koehler, Jonathan Mathias, Norio Komatsu, Robert N. Boothroyd, Amber Spierer, Julian Perez Ronco, Gavin Taylor-Stokes, John Waller & Ruben A. Mesa. (2017) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Annals of Hematology 96:10, pages 1653-1665.
Crossref
Crossref
Ruben A. Mesa, Carole B. Miller, Maureen Thyne, James Mangan, Sara Goldberger, Salman Fazal, Xiaomei Ma, Wendy Wilson, Dilan C. Paranagama, David G. Dubinski, Ahmad Naim, Shreekant Parasuraman, John Boyle & John O. Mascarenhas. (2017) Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Cancer 123:3, pages 449-458.
Crossref
Crossref
Ruben Mesa, Alessandro M. Vannucchi, Abdulraheem Yacoub, Pierre Zachee, Mamta Garg, Roger Lyons, Steffen Koschmieder, Ciro Rinaldi, Jennifer Byrne, Yasmin Hasan, Francesco Passamonti, Srdan Verstovsek, Deborah Hunter, Mark M. Jones, Huiling Zhen, Dany Habr & Bruno Martino. (2017) The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). British Journal of Haematology 176:1, pages 76-85.
Crossref
Crossref
Andreas Reiter & Claire Harrison. (2016) How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. Current Hematologic Malignancy Reports 11:5, pages 356-367.
Crossref
Crossref
Ruben Mesa, Srdan Verstovsek, Jean‐Jacques Kiladjian, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Huiling Zhen, Mark M. Jones, Shreekant Parasuraman, Jingjin Li, Isabelle Côté, Dany Habr & Alessandro M. Vannucchi. (2016) Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. European Journal of Haematology 97:2, pages 192-200.
Crossref
Crossref
Nana Brochmann, Ann-Dorthe Zwisler, Mette Kjerholt, Esben Meulengracht Flachs, Hans Carl Hasselbalch & Christen Lykkegaard Andersen. (2015) A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms. Quality of Life Research 25:4, pages 835-846.
Crossref
Crossref
Robyn M. Scherber, Heidi E. Kosiorek, Zhenya Senyak, Amylou C. Dueck, Matthew M. Clark, Michael A. Boxer, Holly L. Geyer, Archie McCallister, Mary Cotter, Barbara Van Husen, Claire N. Harrison & Ruben A. Mesa. (2015) Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer 122:3, pages 477-485.
Crossref
Crossref
Brady L. SteinStephen T. OhDmitriy BerenzonGabriela S. HobbsMarina KremyanskayaRaajit K. RampalCamille N. AbboudKenneth AdlerMark L. HeaneyElias J. JabbourRami S. KomrokjiAlison R. MoliternoEllen K. RitchieLawrence RiceJohn MascarenhasRonald Hoffman. (2015)
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of
JAK2 V617F
. Journal of Clinical Oncology 33:33, pages 3953-3960.
Crossref
Crossref
Lesley A. Anderson, Glen James, Andrew S. Duncombe, Ruben Mesa, Robyn Scherber, Amylou C. Dueck, Frank de Vocht, Mike Clarke & Mary F. McMullin. (2015) Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls. American Journal of Hematology 90:10, pages 864-870.
Crossref
Crossref
Brady L. Stein, Alison R. Moliterno & Ramón V. Tiu. (2014) Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Annals of Hematology 93:12, pages 1965-1976.
Crossref
Crossref
Holly Geyer & Ruben A. Mesa. (2014) Assessing disease burden in patients with classic MPNs. Best Practice & Research Clinical Haematology 27:2, pages 107-119.
Crossref
Crossref
Hans C. Hasselbalch. (2013) The role of cytokines in the initiation and progression of myelofibrosis. Cytokine & Growth Factor Reviews 24:2, pages 133-145.
Crossref
Crossref
Esther Natalie Oliva, Andrea Piccin, Maria Gabriella Mazzucconi, Enrica Morra, Umberto Recine, Enrico Maria Pogliani, Fabrizio Pane, Marco Gobbi, Luigi Gugliotta, Mauro Krampera, Nicola Cascavilla, Rossella Cacciola, Emma Cacciola, Giuseppe Fioritoni, Renato Fanin, Anna Marina Liberati, Emanuele Angelucci & Sante Tura. (2011) Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. Annals of Hematology 91:4, pages 527-532.
Crossref
Crossref